次世代免疫腫瘍学カンファレンス 2024 – ボストン：ハイライトとイベント総括

The 7th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference 2024 was held in Boston, MA on 20-21 June, 2024. The event brought together academics and scientists from research institutes and biopharmaceutical companies to discuss the latest updates, challenges, and future directions in immuno-oncology research. Topics discussed included: 

• Updates in development of ADC’s and Bispecific Ab’s 

• Immune Checkpoint Inhibitors and Combinations 

• Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators) 

• Biomarkers and Personalized Medicine in IO 

• CAR-T Cell therapy, TCR Based-Cell Therapy 

• Tumor microenvironment and Oncolytic Viruses 

→ Biointron’s Highlighted Points: 

1. Antibody Therapy Developments

• Anchored immunotherapy within the tumor microenvironment results in prolonged drug retention and limited systemic toxicity; aluminium hydroxide as a stable anchoring scaffold.

• Potential side effects of immunotherapies and best safety practices for managing them were discussed. (@Indaptus Therapeutics)  

• B7-H7, a novel checkpoint axis for therapeutic targeting in cancer, suppresses T and NK cell activation through a novel immunosuppressive receptor.

• Many of the recently approved or investigated approaches for melanoma immunotherapy require more answers to develop and enhance effective memory response against cancer cells.

2. Pre-clinical and Translational IO & Immune Checkpoint Blockades 

• Polyploid giant cancer cells (PGCCs) are responsible for tumor progression, metastasis, chemoresistance and relapse. Key molecular pathways, therapeutic strategies, and computational methods were discussed.

• Challenges and opportunities for the development of ADCs, bispecific immunomodulatory therapies, and combination; challenges to attaining the best therapeutic index.

• Intrinsic differences in tumor biology due to post translation modifications and protein-protein interactions lead to racial disparity in breast cancer - understanding this can help in designing precision medicines.

• Novel antibody-enabled targeted protein stabilization (TPS2) augments anti-tumor immune response by delivering Cbl-b inhibitor to immune cells while blocking checkpoint molecule, PD1.

Thank you for visiting us at our booth in NGIO 2024 to learn about our services! We had a great time connecting with you and understanding how we can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.